Proceedings of the 13th International Conference on Thrombosis and Hemostasis Issues in Cancer, 2026
Vol. 5 No. s1 (2026)
Next-generation biomarkers for cancer-associated thrombosis prediction: the role of non-genomic-omics
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 16 April 2026
2
Views
0
Downloads
Authors
Prediction of cancer-associated thrombosis (CAT) remains a major clinical challenge. Although genomic data and clinic-genetic scores have advanced understanding, they do not explain all inter-individual variability in CAT risk. Non-genomic omics, including proteomics, transcriptomics and epigenomics, capture complementary, dynamic biological information that can improve risk stratification. In summary, genomics contributes one piece of a much larger puzzle, necessary, informative, but fundamentally insufficient when used alone to understand, predict or manage CAT. This review synthesizes recent evidence on these non-genomic–omics for CAT prediction, highlights current limitations (validation, standardization, causal inference) and outlines priorities for translational development and clinical validation.
Downloads
Download data is not yet available.
Citations
1. Khorana AA, Kuderer NM, Culakova E, et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008;111:4902-7. DOI: https://doi.org/10.1182/blood-2007-10-116327
2. Mulder FI, Candeloro M, Kamphuisen PW, et al. The Khorana score for prediction of venous thromboembolism in cancer patients: A systematic review and meta-analysis. Haematologica 2019;104:1277-87. DOI: https://doi.org/10.3324/haematol.2018.209114
3. Klarin D, Busenkell E, Judy R, et al. Genome-wide association analysis of venous thromboembolism identifies new risk loci and genetic overlap with arterial vascular disease. Nat Genet 2019;51:1574-9. DOI: https://doi.org/10.1038/s41588-019-0519-3
4. Muñoz A, Ay C, Grilz E, et al. A clinical-genetic risk score for predicting cancer-associated venous thromboembolism: development and validation in two prospective cohorts (ONCOTHROMB). J Clin Oncol 2023;41:2911-25. DOI: https://doi.org/10.1200/JCO.22.00255
5. Sabater-Lleal M, Thibord F, de Vries PS, et al. Historical review: more than two decades understanding the genetic architecture of hemostasis and thrombosis. J Thromb Haemost 2026;24:11104-17. DOI: https://doi.org/10.1016/j.jtha.2025.11.006
6. Agnelli G, Gussoni G, Bianchini C, et al. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: A randomised, placebo-controlled, double-blind study. Lancet Onc. 2009;10:943-9. DOI: https://doi.org/10.1016/S1470-2045(09)70232-3
7. Wang TF, Zwicker JI, Ay C, et al. The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: Guidance from the SSC of the ISTH. J Thromb Haemost 2019;17:1772-78. DOI: https://doi.org/10.1111/jth.14564
8. Key NS, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline update. J Clin Oncol 2023;41:3063-71. DOI: https://doi.org/10.1200/JCO.23.00294
9. Kim AS, Khorana AA, McCrae KR. Mechanisms and biomarkers of cancer-associated thrombosis. Transl Res 2020;225:33-53. DOI: https://doi.org/10.1016/j.trsl.2020.06.012
10. Demers M, Krause DS, Schatzberg D, et al. Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis. Proc Natl Acad Sci USA 2012;109:13076-81. DOI: https://doi.org/10.1073/pnas.1200419109
11. Ender F, Freund A, Quecke T, et al. Tissue factor activity on microvesicles from cancer patients. J Cancer Res Clin Oncol 2020;146:467-75. DOI: https://doi.org/10.1007/s00432-019-03073-0
12. Cui C, Wang G, Yang S, et al. Tissue factor-bearing microparticles and the risk of venous thrombosis in cancer patients: A meta-analysis. Sci Rep 2018;8:1675. DOI: https://doi.org/10.1038/s41598-018-19889-8
13. Wan T, Song J, Zhu D, et al. Cancer-associated venous thromboembolism: a comprehensive review. Thromb J 2025;23:35. DOI: https://doi.org/10.1186/s12959-025-00719-7
14. Roy DC, Wang T-F, Lun R, Zahrai A, et al. Circulating blood biomarkers and risk of venous thromboembolism in cancer patients: a systematic review and meta-analysis. Thromb Haemost 2024;124:1117-33. DOI: https://doi.org/10.1055/a-2330-1371
15. Connolly GC, Phipps RP, Francis CW. Risk factors, biomarkers and a risk score for cancer-associated thrombosis. Thromb Res 2010;125:S1-S7. DOI: https://doi.org/10.1016/S0049-3848(10)00227-6
16. Ay C, Dunkler D, Simanek R, et al. Prediction of venous thromboembolism in patients with cancer by measuring thrombin generation: Results from the Vienna Cancer and Thrombosis Study. J Clin Oncol 2011;29:2099-103. DOI: https://doi.org/10.1200/JCO.2010.32.8294
17. Yang M, Wang H, Qin W, et al. Increased D-dimer predicts the risk of cancer-associated recurrent venous thromboembolism and venous thromboembolism: A systematic review and meta-analysis. Thromb Res 2020;196:410-3. DOI: https://doi.org/10.1016/j.thromres.2020.09.031
18. Yi J, Chen H, Li J, et al. The association between ROS1 rearrangement and risk of thromboembolic events in patients with advanced non-small cell lung cancer: A multicenter study in China. Thromb J 2022;20:56. DOI: https://doi.org/10.1186/s12959-022-00417-8
19. Yuan S, Xu F, Zhang H, et al. Proteomic insights into modifiable risk of venous thromboembolism and cardiovascular comorbidities. J Thromb Haemost 2024;22:738-48. DOI: https://doi.org/10.1016/j.jtha.2023.11.013
20. Liu Y, Gao L, Fan Y, et al. Discovery of protein biomarkers for venous thromboembolism in non-small cell lung cancer patients through data-independent acquisition mass spectrometry. Front Oncol 2023;13:1079719. DOI: https://doi.org/10.3389/fonc.2023.1079719
21. Chen K, Zhang Y, Zhang L, et al. Machine learning models for risk prediction of cancer-associated thrombosis: A systematic review and meta-analysis. J Thromb Haemost 2025;23:610-26. DOI: https://doi.org/10.1016/j.jtha.2024.11.001
22. Lottin M, Soudet S, Fercot J, et al. Molecular landscape of the coagulome of oral squamous cell carcinoma. Cancers (Basel) 2022;14:460. DOI: https://doi.org/10.3390/cancers14020460
23. Fernández Turizo MJ, Patell R, Zwicker JI. Identifying novel biomarkers using proteomics to predict cancer-associated thrombosis. Bleeding Thromb Vasc Biol 2024;3:120. DOI: https://doi.org/10.4081/btvb.2024.120
24. Puram SV, Tirosh I, Parikh AS, et al. Single-cell transcriptomic analysis of primary and metastatic tumor ecosystems in head and neck cancer. Cell 2017;171:1611-24. DOI: https://doi.org/10.1016/j.cell.2017.10.044
25. Bosch FTM, Dijk F, Briedé S, et al. Tumor gene expression is associated with venous thromboembolism in patients with ductal pancreatic adenocarcinoma. Thromb Res 2025;246:109240. DOI: https://doi.org/10.1016/j.thromres.2024.109240
26. Beitzen-Heineke A, Muller MA, Xia Y, et al. A platelet transcriptomic signature of thromboinflammation predicts cardiovascular risk. JCI Insight 2025;10:e195824. DOI: https://doi.org/10.1172/jci.insight.195824
27. Hernández-Lemus E, Ochoa S. Methods for multi-omic data integration in cancer research. Front Genet 2024;15:1425456. DOI: https://doi.org/10.3389/fgene.2024.1425456
28. Sun C, Cheng X, Xu J, et al. A review of disease risk prediction methods and applications in the omics era. Proteomics 2024;24:e2300359. DOI: https://doi.org/10.1002/pmic.202300359
29. Noë M, Mathios D, Annapragada AV, et al. DNA methylation and gene expression as determinants of genome-wide cell-free DNA fragmentation. Nat Commun 2024;15:6690. DOI: https://doi.org/10.1038/s41467-024-50850-8
30. Shen SY, Singhania R, Fehringer G, et al. Sensitive tumour detection and classification using plasma cell-free DNA methylomes. Nature 2018;563:579-83. DOI: https://doi.org/10.1038/s41586-018-0703-0
31. Unruh D, Mirkov S, Wray B, et al. Methylation-dependent tissue factor suppression contributes to the reduced malignancy of IDH1-mutant gliomas. Clin Cancer Res 2019;25:747-59. DOI: https://doi.org/10.1158/1078-0432.CCR-18-1222
32. Anijs RJS, El Houari Laghmani L, Ünlü B, et al. Tumor-expressed microRNAs associated with venous thromboembolism in colorectal cancer. Res Pract Thromb Haemost 2022;6:e12749. DOI: https://doi.org/10.1002/rth2.12749
33. Tavares V, Savva-Bordalo J, Rei M, et al. Plasma microRNA environment linked to tissue factor pathway and cancer-associated thrombosis: prognostic significance in ovarian cancer. Biomolecules 2024;14:928. DOI: https://doi.org/10.3390/biom14080928
34. Anijs RJS, Nguyen YN, Cannegieter SC, et al. MicroRNAs as prognostic biomarkers for (cancer-associated) venous thromboembolism. J Thromb Haemost 2023;21:7-17. DOI: https://doi.org/10.1016/j.jtha.2022.09.001
35. Pharo H, Vedeld HM, Sjurgard IV, et al. From concept to clinic: a roadmap for DNA methylation biomarkers in liquid biopsies. Oncogene 2025;44:4814-31. DOI: https://doi.org/10.1038/s41388-025-03624-5
36. Jiang X, Zeleznik OA, Lindström S, et al. Metabolites associated with the risk of incident venous thromboembolism: a metabolomic analysis. J Am Heart Assoc 2018;7:e010317. DOI: https://doi.org/10.1161/JAHA.118.010317
37. Liu Q, Yang F, Kong K, Lu F. Potential causal relationships between blood metabolites, inflammatory cytokines, and venous thromboembolism. Front Immunol 2024;15:1445790. DOI: https://doi.org/10.3389/fimmu.2024.1445790
38. Deguchi H, Banerjee Y, Trauger S, et al. Acylcarnitines are anticoagulants that inhibit factor Xa and are reduced in venous thrombosis, based on metabolomics data. Blood 2015;126:1595-600. DOI: https://doi.org/10.1182/blood-2015-03-636761
39. Zhang K, Wang P, Huang W, et al. Integrated landscape of plasma metabolism and proteome of patients with post-traumatic deep vein thrombosis. Nat Commun 2024;15:7831. DOI: https://doi.org/10.1038/s41467-024-52262-0
40. Belghasem M, Roth D, Richards S, et al. Metabolites in a mouse cancer model enhance venous thrombogenicity through the aryl hydrocarbon receptor-tissue factor axis. Blood 2019;134:2399-413. DOI: https://doi.org/10.1182/blood.2019001675
41. Hasan RA, Koh AY, Zia A. The gut microbiome and thromboembolism. Thromb Res 2020;189:77-87. DOI: https://doi.org/10.1016/j.thromres.2020.03.003
42. Zhu W, Gregory JC, Org E, et al. Gut microbial metabolite trimethylamine N-oxide enhances platelet hyperreactivity and thrombosis risk. Cell 2016;165:111-24. DOI: https://doi.org/10.1016/j.cell.2016.02.011
43. Xi L, Wang H, Du J, et al. Causal effect of gut microbiota on venous thromboembolism: A two-sample Mendelian randomization study. Thromb J 2024;22:106. DOI: https://doi.org/10.1186/s12959-024-00676-7
Supporting Agencies
This work was supported by Networking Biomedical Research Centre in the subject areas of Rares Diseases (CIBERER CB23/07/00042) initiatives of Instituto de Investigación Carlos III (ISCIII), 2021 SGR00830 from Generalitat de Catalunya, the Spanish Government Instituto de Salud Carlos III and Fondo de Investigación Sanitaria (ISCIII-FIS) (PI24/00682), CERCA Programme/Generalitat de Catalunya, and the nonprofit association Activa’TT por la Salud.How to Cite
1.
Soria JM, Souto JC, Muñoz A. Next-generation biomarkers for cancer-associated thrombosis prediction: the role of non-genomic-omics. Bleeding Thromb Vasc Biol [Internet]. 2026 Apr. 16 [cited 2026 Apr. 19];5(s1). Available from: https://www.btvb.org/btvb/article/view/447
Copyright (c) 2026 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
